Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic disease characterised by aberrant fibroblast/myofibroblast accumulation and excessive collagen matrix deposition in the alveolar areas of lungs. As the first approved IPF medication, pirfenidone (PFD) significantly decelerates...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Hsiao-Yen, Vander Heiden, Jason A., Uttarwar, Salil, Xi, Ying, N'Diaye, Elsa-Noah, LaCanna, Ryan, Caplazi, Patrick, Gierke, Sarah, Moffat, John, Wolters, Paul J., Ding, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133585/
https://www.ncbi.nlm.nih.gov/pubmed/36585256
http://dx.doi.org/10.1183/13993003.00604-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133585/
https://www.ncbi.nlm.nih.gov/pubmed/36585256
http://dx.doi.org/10.1183/13993003.00604-2022

Ejemplares similares